4 Activity of galeterone in castrate-resistant prostate cancer (CRPC) with C-terminal AR loss: Results from ARMOR2
暂无分享，去创建一个
E. Antonarakis | E. Heath | V. Njar | O. Sartor | A. Hussain | W. Edenfield | M. Taplin | R. Pili | K. Chi | B. Montgomery | M. Rettig | D. Marrinucci | N. Shore | U. Emmenegger | D. Lipsitz | A. Koletsky | L. Nordquist | F. Chu | J. Cochran | K. Mamlouk